Landmark procedure expands access to next-generation personalized immunotherapy for patients in Gujarat
Ahmedabad (Gujarat) [India], July 17: HCG Aastha Cancer Centre, Ahmedabad, achieved a significant milestone in advanced cancer care with the successful completion of its first CAR-T Cell Therapy on a patient diagnosed with Primary Refractory Lymphoma, an aggressive blood cancer that had not responded to conventional treatment. This landmark achievement marked another step towards making one of the world’s most advanced forms of personalized cancer treatment accessible to patients across Gujarat and neighbouring regions.
The CAR-T Cell Therapy programme at HCG Aastha Cancer Centre is led by Dr. Kaumil Patel, Consultant -Hematology, Bone Marrow Transplantation (BMT) & CAR-T Cell Therapy Specialist, along with a dedicated multidisciplinary team trained in advanced cellular therapies and the comprehensive management of complex hematological malignancies. The patient’s treatment was successfully completed under the team’s expertise, marking the centre’s first successful CAR-T Cell Therapy procedure.
Dr. Kaumil Patel, Consultant, Hematology, Bone Marrow Transplantation (BMT) & CAR-T Cell Therapy Specialist, HCG Aastha Cancer Centre, Ahmedabad, said: “The successful completion of our first CAR-T Cell Therapy reflects the evolution of blood cancer treatment from conventional approaches to precision immunotherapy. For patients with relapsed or refractory lymphoma, this therapy offers a meaningful opportunity when other treatment options have failed. More importantly, it demonstrates that highly specialized cellular therapies can now be delivered safely with international standards of care, enabling patients to access advanced treatment much closer to home.”
CAR-T Therapy is one of the most advanced forms of personalized cancer immunotherapy available today. The treatment involves collecting a patient’s own T-cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them into the patient. This highly specialized therapy has transformed treatment outcomes for patients with aggressive blood cancers that have failed conventional treatment options such as chemotherapy and immunotherapy.
The successful completion of CAR-T Cell Therapy requires sophisticated infrastructure, multidisciplinary expertise, advanced transfusion and cellular therapy support, dedicated intensive monitoring facilities, and specialized management of treatment-related complications. Only a limited number of centres in Gujarat currently possess the expertise, infrastructure, and clinical capabilities required to safely perform CAR-T Cell Therapy and manage its associated complexities.
Dr Bharat Gadhavi, Regional Director, Gujarat & Jaipur, HCG said: ” our commitment to continuously strengthening our clinical capabilities and investing in advanced oncology services that directly benefit patients. Establishing a CAR-T Cell Therapy programme requires far more than technology, it demands specialized expertise, integrated infrastructure, and coordinated multidisciplinary care. Successfully delivering this therapy reinforces our vision of bringing world-class cancer treatment within reach for patients across Gujarat and surrounding regions.”
The patient said, “The journey has not been easy, but I never felt alone. From the very beginning, the doctors and hospital staff supported me with compassion, answered every question patiently, and gave me the confidence to move forward. I sincerely thank the entire team at HCG Aastha Cancer Centre for giving me hope and helping me look ahead with optimism.”
Sudarshan Bhamare, Chief Operating Officer, HCG Aastha Cancer Centre, Ahmedabad ,The successful completion of the procedure reflected HCG Aastha Cancer Centre’s commitment to providing comprehensive hematology, hemato-oncology, bone marrowtransplantation, and advanced cellular therapy services at standards comparable to leading international cancer centres.
CAR-T Cell Therapy may be considered for carefully selected patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), Primary Refractory Aggressive B-Cell Lymphomas, High-Grade B-Cell Lymphoma, selected cases of Follicular Lymphoma and Mantle Cell Lymphoma, relapsed B-Cell Acute Lymphoblastic Leukemia (ALL), and selected patients with Multiple Myeloma after multiple prior lines of therapy.
By expanding access to advanced cellular therapies such as CAR-T Cell Therapy, HCG Aastha Cancer Centre continued to strengthen its commitment to delivering innovative, evidence-based, and patient-centric cancer care while making transformative treatments accessible closer to home.
About HCG Aastha Cancer Centre, Ahmedabad
HCG Aastha Cancer Centre is a comprehensive cancer care hospital offering multidisciplinary oncology services including Medical Oncology, Surgical Oncology, Radiation Oncology, Hematology, Bone Marrow Transplantation (BMT), Cellular Therapies, Precision Oncology, Diagnostic Services, and supportive cancer care. The centre is committed to delivering advanced cancer treatment through innovation, expertise, and compassionate patient care.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
